CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine Anti-IGF-1R monoclonal antibody, mAVE1642

Journal of Immunology

Volumn 177, Issue 6, 2006, Pages 4218-4223

  Descamps, Géraldine ^a   Wuillème Toumi, Soraya ^a   Trichet, Valérie ^c   Venot, Corinne ^d   Debussche, Laurent ^d   Hercend, Thierry ^d   Collette, Madeleine ^a   Robillard, Nelly ^b   Bataille, Régis ^a   Amiot, Martine ^a,c  

^a UNIVERSITÉ DE NANTES   (France)

^b Laboratoire d'Hematologie   (France)

^c INSERM   (France)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAVE1642; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SENSITIZATION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; CELL LINE, TUMOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MULTIPLE MYELOMA; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 33748511674     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.6.4218     Document Type: Article

References (24)

1. Georgii-Hemming, P., H. J. Wiklund, O. Ljunggren, and K. Nilsson. 1996. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 88: 2250-2258.
2. Ge, N. L., and S. Rudikoff. 2000. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 96: 2856-2861.
3. Ferlin, M., N. Noraz, C. Hertogh, J. Brochier, N. Taylor, and B. Klein. 2000. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6. independent transduction pathway. Br. J. Haematol. 111: 626-634.
4. Hsu, J., V. Shi, S. Krajewski, S. Renner, M. Fisher, J. C. Reed, T. F. Franke, and A. Lichtenstein. 2001. The AKT kinase is activated in multiple myeloma tumor cell. Blood 98: 2853-2855.
5. Pollak, M. N., E. S. Schernhammer, and S. E. Hankinson. 2004. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer. 4: 505-518.
6. Tu, Y., A. Gardner, and A. Liehtenstein. 2000. The phosphatidylinositol 3-kinase/ AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 60: 6763-6770.
7. Hideshima, T., N. Nakamura, D. Chauhan, and K. C. Anderson. 2001. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20: 5991-6000.
8. Descamps, G., C. Pellat-Deceunynck, Y. Szpak, R. Bataille, N. Robillard, and M. Amiot. 2004. The magnitude of Akt/phosphatidylinositol-3′-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J. Immunol. 173: 4953-4959.
9. Kulas, D. T., G. G. Freund, and R. A. Mooney. 1996. The transmembrane protein-tyrosine phosphatase CD45 is associated with, decreased insulin receptor signaling. J. Biol. Chem. 271: 755-760.
10. Moreau, P., N. Robillard, H. Avet-Loiseau, D. Pineau, N. Morineau, N. Milpied, J. L. Harousseau, and R. Bataille. 2004. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 89: 547-551.
11. Ishikawa H., N. Tsuyama, S. Abroun, S. Liu, F. J. Li, O. Taniguchi, and M. M. Kawano. 2002. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 99: 2172-2178.
12. Bataille, R., N. Robillard, C. Pellat-Deceunynck, and M. Amiot. 2003. A cellular model for myeloma cell growth and maturation based on an intra-clonal CD45 hierarchy. Immunol. Rev. 194: 105-111.
13. Robillard, N., C. Pellat-Deceunynck, R. Bataille. 2005. Phenotypic characterization of the human myeloma cell growth fraction. Blood 105: 4845-4548.
14. Mitsiades, C. S., N. S. Mitsiades, C. J. McMullan, V. Poulaki, R. Shringarpure, M. Akiyama, T. Hideshima, D. Chauhan, M. Joseph, T. A. Libermann, et al. 2004. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230.
15. Vasilcanu D., A. Gimita, L. Girnita, R. Vasilcanu, M. Axelson, and O. Larsson. 2004. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor: link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23: 7854-7862.
16. Baserga R. 2005. The insulin-like growth factor-1 receptor as target for cancer therapy. Expert Opin. Ther. Targets 4: 753-768.
17. Maloney, E. K., J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X-M. Zhou, W. A. BlŠttler, T. Chittenden, and R. Singh. 2003. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63: 5073-5083.
18. Burtrum, D., Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al. 2003. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63: 8912-8921.
19. Way, B. A., and R. A. Mooney. 1993. Activation of phosphatidylinositol-3- kinase by platelet-derived growth factor and insulin-like growth factor-1 is inhibited by a transmembrane phosphotyrosine phosphatase. J. Biol. Chem. 268: 26409-26415.
20. Mooney, R. A., G. G. Freund, B. A. Way, and K. L. Bordwell. 1992. Expression of a transmembrane phosphotyrosine phosphatase inhibits cellular response to platelet-derived growth factor and insulin-like growth factor-1. J. Biol. Chem. 267: 23443-23446.
21. Bähr, C., and B. Groner. 2004. The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Hormone and IGF Research 14: 287-295.#
22. Surmacz, E. 2003. Growth factor receptors as therapeutic targets: strategies to inhibits the IGF-1R. Oncogene 22: 6589-6597.
23. Toi, M., K. Horiguchi, H. Bando, S. Saji, and L. W. Chow. 2005. Trastuzumab: updates and future issues. Cancer Chemother. Pharmacol. 56(Suppl.1): 94-99.
24. Garcia-Saenz, J A., M. Martín, J. Puente, S. Lopez-Tarruella, A. Casado, F. Moreno, E. Grande, and E. Diaz-Rubio. 2005. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin. Breast Cancer 6: 325-329.